InsidersTradesSigma
申报总数
公司
▲ 买入（1 笔）
▼ 卖出（1 笔）
内部人交易记录
高级管理人员已披露买入
1
已披露卖出
1
T+90 胜率
100%
T+90 平均收益
+10.4%
基于 1 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
信号历史
Discover the full record of transactions filed by Bios Equity COF, LP, Director. Director active across 1 company, notably Actuate Therapeutics, INC.. In total, 3 reports have been recorded. Split: 1 buy · 1 sell. Total volume traded: €466k. Activity tracked since 14 August 2024. The latest transaction was filed on 27 June 2025 (Acquisition). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Bios Equity COF, LP
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报3 总计
71,428 股@ US$7.000.68% mcap50.0% 占其流量Common StockSEC:0001104659-25-063993:0
标准退出：2025年9月25日 (T+90)
5,314 股@ US$8.004.3% 占其流量Common StockSEC:0001104659-24-091372:0
884,427 股Common StockSEC:0001104659-24-089825:0
3 条申报中的 3 条
About Bios Equity COF, LP
Bios Equity COF, LP is a Director at Actuate Therapeutics, Inc. As a board member, it contributes to the governance of the company and strategic decision-making. Its experience in the financial sector allows it to provide valuable insights.
